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OBJECTIVES We sought to review the emerging data and the clinical rationale for combining glycoprotein
(GP) IIb/IIIa inhibitors with thrombolytic therapy for acute myocardial infarction (AMI).
BACKGROUND Although thrombolytic therapy has been a major advance in the treatment of acute ST
segment elevation MI, new single-bolus thrombolytic agents have been unable to break the
“thrombolytic ceiling” in infarct-related artery (IRA) patency.
METHODS Recent literature on GPIIb/IIIa inhibitors in acute coronary syndromes was reviewed.
RESULTS A new approach toward improving current thrombolytic–antithrombotic regimens focuses on
“targeted therapy” for each component of the occlusive coronary thrombus: fibrin, thrombin
and platelets. For the fibrin component, front-loading and/or bolus dosing of plasminogen
activators (PAs) has identified the currently available doses of tissue-type plasminogen
activator (t-PA) and recombinant tissue-type plasminogen activator (r-PA). For the thrombin
component, several recent trials have shown that lower doses of heparin improve the safety
profile of the thrombolytic-antithrombotic regimen. For the platelet component, aspirin has
been shown to be effective, but the GPIIb/IIIa inhibitors offer the potential for more effective
platelet inhibition and improved clinical efficacy. The benefits of GPIIb/IIIa inhibition in
reducing death, MI or urgent revascularization in the setting of percutaneous coronary
intervention are well established. Emerging experimental and clinical data now suggest that
combining GPIIb/IIIa inhibition with reduced-dose thrombolytic therapy may improve early
IRA patency without increasing bleeding risk.
CONCLUSIONS Given the strong clinical and physiologic rationale, clinical investigation in acute ST segment
elevation MI is currently focused on combining the potent GPIIb/IIIa receptor inhibitors
with reduced-dose fibrinolytic agents in acute MI, with the goal of overcoming “thrombolytic
resistance.” (J Am Coll Cardiol 1999;34:1395–402) © 1999 by the American College of
Cardiology
Although thrombolytic therapy is a mainstay of treatment
for acute myocardial infarction (AMI), it has well-
documented limitations. With current thrombolytic regi-
mens, patency is restored in 60% to 85% of patients with
AMI (1–4), and only 54% to 60% of patients achieve full
myocardial reperfusion, angiographically defined as Throm-
bolysis In Myocardial Infarction trial (TIMI) flow grade 3
in the infarct-related artery (IRA) (1–4). Beyond TIMI
flow grade 3, full myocardial perfusion is not present in all
patients, leaving only 30% to 45% of patients with truly
optimal reperfusion (5,6). In addition, reocclusion or rein-
farction, or both, occurs in roughly 30% of patients by three
months (7–9), which is associated with increased mortality
(10–11). Finally, thrombolytic therapy is associated with
increased risk of bleeding complications, including intracra-
nial hemorrhage (ICH), which ranges from 0.5% to 0.9% in
major randomized trials (2,3,12,13), but may be higher in
clinical practice.
THROMBOLYTIC RESISTANCE
Rupture or erosion of lipid-rich atherosclerotic plaques
exposes the subendothelial plaque components to blood.
The ensuing platelet adhesion and activation lead to
changes in platelet shape, release of thromboxane A2
(TxA2), plasminogen activator inhibitor-1 (PAI-1), seroto-
nin and other proaggregatory substances. In addition, con-
formational changes in the glycoprotein (GP) IIb/IIIa
receptor occur, making the receptor receptive to ligand
binding. Platelet aggregation at the rupture site leads to the
buildup of occlusive thrombi that can cause myocardial
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ischemia, infarction and subsequent complications. This has
been confirmed in recent angioscopic studies, showing that
a substantial portion of occlusive thrombi (previously
thought to consist only of fibrin-rich “red” clot) is made up
of platelets (the so-called “white” clot) (14).
The generation of thrombin and activation of platelets at
the site of vascular injury frequently limit thrombolytic
therapy. This “thrombolytic resistance” may be due to
several mechanisms (Fig. 1): 1) incomplete lysis of the clot
because plasminogen activators act only on the fibrin por-
tion of thrombi; 2) platelets that elaborate PAI-1, which
inhibits the action of the thrombolytic agent, and platelets
that release TxA2, which causes vasoconstriction and may
limit recanalization of the IRA; 3) exposure of clot-bound
thrombin can cleave fibrinogen to fibrin, thereby facilitating
rethrombosis; and 4) thrombolytic therapy’s direct platelet-
activating effect, leading to increased levels of TxA2 and
platelet-activating factor (15). Thus, fibrinolysis promotes
platelet activation by creating conditions that actually trig-
ger rethrombosis or reocclusion, or both.
“TARGETED THERAPY” FOR AMI
With the understanding of the three major physiologic
components of the coronary thrombus—fibrin, thrombin
and platelets—therapy is now being targeted at each com-
ponent of the clot (Fig. 2).
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
GP 5 glycoprotein
GUSTO 5 Global Utilization of Streptokinase and
TPA for Occluded arteries
ICH 5 intracranial hemorrhage
IRA 5 infarct-related artery
MI 5 myocardial infarction
PAI-1 5 plasminogen activator inhibitor-1
PCI 5 percutaneous coronary intervention
r-PA 5 recombinant plasminogen activator
TIMI 5 Thrombolysis In Myocardial Infarction
TNK-tpa 5 TNK–tissue-type plasminogen activator
t-PA 5 tissue-type plasminogen activator
TxA2 5 thromboxane A2
Figure 1. Thrombolytic resistance. FDP 5 fibrin/fibrinogen degradation product. (Adapted with permission from Moliterno DJ, Topol
EJ. Thromb Haemost 1997;78:214–9.)
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Thrombolytic therapy with plasminogen activators is
better termed “fibrinolytic” therapy, because it generates
plasmin, which degrades fibrin to lyse the clot. Initial efforts
to improve thrombolysis with higher doses of tissue-type
plasminogen activator (t-PA) did not lead to improvement
(16). Newer thrombolytic agents, such as lanoteplase
(n-PA) (17) and TNK-tPA (TNK–tissue-type plasminogen
activator) (18), appear to be similar to t-PA or reteplase
(r-PA) when given with aspirin and heparin.
The second component of thrombolytic-antithrombin
therapy is heparin. For acute ST segment elevation myo-
cardial infarction (MI), heparin is an important adjunctive
agent to maintain patency after t-PA (19–21). The benefit
of heparin is believed to be due to decreased reocclusion
(22). Heparin has been used in conjunction with all variants
of t-PA, including r-PA (4,13), n-PA (17) and TNK-tPA
(18). Further support for the use of heparin after t-PA
administration comes from the benefit observed in the
Global Utilization of Streptokinase and TPA for Occluded
arteries (GUSTO-I) (23) and TIMI-4 (3) trials, as com-
pared with the lack of benefit in the International Study of
Infarct Survival-3 (ISIS-3) and Gruppo Italiano per lo
Studio della Sopravvivenza nell’Infarto miocardico-2
(GISSI-2) trials, where intravenous heparin was not used
with t-PA (24,25). When reduced doses of heparin are used
in conjunction with thrombolysis, reduced rates of ICH and
major hemorrhage have been observed in four separate trials
(18,26–28). Indeed, the update to the American College of
Cardiology/American Heart Association (ACC/AHA)
Guideline for the Management of AMI recommends a new
lower dose of heparin: bolus of 60 U/kg (maximum
4,000 U) and an initial infusion of 12 U/kg per h (maximum
1,000 U/h).
Efforts to improve thrombin inhibition by targeting
clot-bound thrombin with direct thrombin inhibitors, such
as hirudin, were studied (TIMI-9B, GUSTO-IIb), but led
to no definitive benefit (26,27). Testing of low molecular
weight heparin plus thrombolysis is under way.
The third component of the “targeted therapy” is anti-
platelet therapy, currently aspirin. Platelet aggregation is
inhibited by aspirin’s ability to permanently acetylate cyclo-
oxygenase, which reduces the formation of TxA2. Aspirin
decreases the risk of IRA reocclusion (29) and reinfarction
(12) after thrombolysis. More important, aspirin has been
shown to reduce mortality by ;25%, an additional benefit
to that achieved by thrombolytic therapy (12). Aspirin’s
dramatic clinical benefits have highlighted the central role
of platelet function in thrombus formation and rethrombo-
sis after thrombolytic therapy. Ticlopidine and clopidogrel
are adenosine diphosphate receptor antagonists that have
benefit as compared with aspirin alone in coronary stenting
and secondary prevention, but they have not yet been
studied in AMI (30). These findings stimulated the devel-
opment of agents with a more direct effect on platelet
aggregation, such as the GPIIb/IIIa antagonists.
THE PROMISE OF ANTIPLATELET
THERAPY WITH GPIIb/IIIa RECEPTOR INHIBITORS
The binding of the GPIIb/IIIa receptor with fibrinogen or
von Willebrand factor represents the final common pathway
of clot formation (Fig. 3). Blockade of these receptors
results in profound suppression of platelet aggregation that
extends beyond the capabilities of aspirin, ticlopidine or
clopidogrel (31).
Abciximab, the Fab fragment of the chimeric antibody to
the GPIIb/IIIa receptor (and to a broader group of inte-
grins) is able to block platelet aggregation as well as inhibit
thrombin generation by tissue factor, the latter due to
blockade of GPIIb/IIIa and alphavbeta3 (32,33). In addi-
tion, there are several peptide and pharmacologic GPIIb/
IIIa receptor inhibitors (tirofiban, eptifibatide and lamifi-
ban). These agents mimic the arginine-lysine-aspartic acid
(RGD) sequence on fibrinogen to inhibit the platelet
GPIIb/IIIa receptor (34,35).
CLINICAL EXPERIENCE WITH
GPIIB/IIIA RECEPTOR INHIBITORS
Glycoprotein IIb/IIIa inhibitors have been shown to inhibit
platelets, increase resolution of coronary thrombus, improve
coronary flow and prevent early recurrent ischemic events
(MI, refractory ischemia or urgent revascularization) (34–
42).
Percutaneous coronary intervention. Numerous trials
have shown that GPIIb/IIIa receptor blockers are beneficial
when used in a wide spectrum of patients undergoing
percutaneous coronary intervention (PCI), and these agents
have been previously reviewed (38–40). The most recent
Figure 2. The three components of coronary thrombus are targets
for therapy. Mechanism of action: aspirin—acetylates cyclooxy-
genase, decreases platelet activation; heparin—reduces clotting
formation/propagation; GPIIb/IIIa inhibitors inhibit platelet ag-
gregation; thrombolytic therapy—converts plasminogen to plas-
min, which dissolves fibrin in clot. LMWH 5 low molecular
weight heparin; t-PA 5 tissue-type plasminogen activator;
r-PA 5 reteplase; SK 5 streptokinase; TNK-tPA 5 TNK–tissue-
type plasminogen activator.
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Figure 3. Platelet adhesion, activation and aggregation and inhibition by GPIIb/IIIa inhibitors. In this diagram of events associated with
platelet adhesion (a), activation (b) and aggregation (c), activated platelets undergo a conformational change in the shape of the GPIIb/IIIa
receptors, which makes them receptive to ligand binding. Fibrinogen binds to the platelet GPIIb/IIIa receptors on adjacent platelets,
forming bridges between them. As shown in (d), GPIIb/IIIa receptor inhibitors block this fibrinogen-binding receptor and therefore
directly prevent platelets from aggregating. AA 5 arachidonic acid; ADP 5 adenosine diphosphate; ASA 5 aspirin; GPIIb/IIIa 5
glycoprotein IIb/IIIa; TXA2 5 thromboxane A2; vWF 5 von Willebrand factor.
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data in PCI come from the Evaluation of Platelet IIb/IIIa
Inhibitor for STENTing (EPISTENT) trial, which found
that the addition of abciximab led to a .50% reduction in
death, MI and urgent revascularization at 30 days, an
absolute reduction of 5.5% (41). Furthermore, one-year
mortality was reduced by abciximab among patients who
received a stent: 1% versus 2.4% for patients with versus
without abciximab (p 5 0.037) (39). One recent meta-
analysis of the 10 large studies showed a 22% reduction in
death and MI at 30 days (40), whereas another showed a
30% reduction in mortality with abciximab (p 5 0.016)
(43). Long-term follow-up is available from one abciximab
trial, and it suggests that benefits are sustained up to three
years (44).
Unstable angina and non–ST segment elevation MI.
Tirofiban and eptifibatide are the two GPIIb/IIIa inhibitors
approved by the Food and Drug Administration for use in
patients with unstable angina or non–ST segment elevation
MI. Tirofiban plus heparin and aspirin reduced the rate of
death, MI or refractory ischemia at seven days by 32% (p 5
0.004) as compared with heparin alone (35). Another trial
showed a significant reduction (p 5 0.04) in the risk of
death or MI at 30 days with eptifibatide as compared with
placebo (34). Abciximab is approved for use in patients with
refractory unstable angina in whom PCI is planned within
24 h. Currently, two large phase III trials are being
conducted in this group of patients testing abciximab and
lamifiban.
New paradigm for benefit of GPIIb/IIIa inhibitors. New
data from two trials show that the addition of the GPIIb/
IIIa inhibitor reduces the amount of coronary thrombus
(36,37) and improves coronary flow (37). There is now a
paradigm shift in the understanding of the benefit of
GPIIb/IIIa inhibitors (Fig. 4): these agents inhibit platelets,
increase resolution of coronary thrombus, improve coronary
flow, enhance myocardial perfusion (45,46) and prevent
early recurrent ischemic events (MI, refractory ischemia or
urgent revascularization) (41,42,44–47). Finally, new data
suggest that these benefits translate into a late mortality
benefit (43).
Adjunct to PCI in ST segment elevation MI. There is
growing experience with the use of GPIIb/IIIa receptor
inhibitors in patients with acute ST segment elevation MI
who undergo PCI. After promising results in an acute MI
subgroup of the Evaluation of IIb/IIIa platelet receptor
antagonist 7E3 in Preventing Ischemic Complications
(EPIC) trial (48), there have now been three trials showing
that abciximab reduces the rate of death, MI or urgent
revascularization by ;50% (46,49,50). In the setting of
rescue PCI, preliminary data analysis from the GUSTO-III
trial showed a reduction in the 30-day mortality rate in a
nonrandomized comparison of those who received abcix-
imab versus those who did not (3.7% vs. 9.8%, p 5 0.04)
(51).
COMBINING GPIIB/IIIA
INHIBITORS WITH THROMBOLYTIC THERAPY
Combining GPIIb/IIIa inhibitors with thrombolytic ther-
apy for acute ST segment elevation MI to accelerate
reperfusion time and reduce the risk of reocclusion is the
subject of active investigation (52–58).
Full-dose thrombolysis plus GPIIb/IIIa inhibition. In
the Thrombolysis and Angioplasty in Myocardial Infarction
(TAMI-8) study, patients received incremental doses of
m7E3, a murine monoclonal antibody to the GPIIb/IIIa
receptor, after receiving t-PA plus heparin and aspirin. A
consistent m7E3 dose-dependent decrease in platelet aggre-
gation was observed and a relationship between receptor
occupancy and extent of platelet inhibition was established.
A dose that achieved 80% to 90% platelet inhibition was
identified. The rate of major hemorrhage was not increased
(53).
In the Integrilin to Manage Platelet Aggregation to
prevent Coronary Thrombosis (IMPACT) trial (n 5 132),
patients received simultaneous eptifibatide and t-PA. Pa-
tients who received eptifibatide at the highest dosage
showed a significantly increased rate of TIMI flow grade 3
in the IRA at 90 min (66% vs. 39% in the placebo group,
p 5 0.006). No differences were seen in the rates of major
or minor bleeding complications, including ICH (54).
However, dosages of eptifibatide used were later found to
achieve only 50% to 60% platelet inhibition.
A subsequent trial combined full-dose streptokinase with
higher dosages of eptifibatide without heparin in patients
(n 5 181) with AMI (55). TIMI flow grade 3 at 90 min was
achieved in 44% to 53% of patients randomized to the three
dosage levels of eptifibatide, as compared with 38% of those
in the placebo group. An increased incidence of bleeding,
most often at the site of arterial puncture, was associated
with increasing dosages of continuous infusion eptifibatide.
There were no occurrences of ICH; however, a 15% rate of
Figure 4. New paradigm for mechanism of benefit of GPIIb/IIIa
inhibitors.
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severe bleeding in patients who received the highest dose of
eptifibatide led to premature discontinuation of that arm.
The Platelet Aggregation Receptor Antagonist Dose
Investigation for reperfusion Gain in Myocardial infarction
(PARADIGM) trial compared different lamifiban dosage
levels to placebo in patients presenting within 12 h of AMI
symptom onset. Patients received aspirin, heparin and either
t-PA or streptokinase at standard dosages (56). Lamifiban
was associated with improved myocardial reperfusion as
measured by early resolution of ST segment elevation.
However, no difference in the composite clinical end point
was noted. Lamifiban was associated with increased rates of
major bleeding.
Reduced-dose thrombolysis plus GPIIb/IIIa inhibition.
The TIMI-14 trial tested the combination of reduced-dose
thrombolysis (using t-PA, streptokinase and r-PA) and
abciximab. In the first phase, 888 patients with MI with ST
segment elevation were randomized within 12 h of symp-
tom onset to one of four reperfusion regimens (each
encompassing several dosage levels): front-loaded t-PA
alone (control arm), reduced-dose t-PA plus abciximab,
reduced-dose streptokinase plus abciximab or abciximab
alone. All patients received aspirin and heparin. The initial
heparin dose was a 70 U/kg bolus with a 15 U/kg per h
infusion in the t-PA control arm and a 60 U/kg bolus with
a 7 U/kg per h infusion in the arms that included abciximab.
Abciximab alone produced TIMI flow grade 3 at 90 min
in 32% of patients and 90-min patency in 48% of patients,
comparable to the rates reported for streptokinase (without
GPIIb/IIIa inhibition), as reported in the TIMI-I and
GUSTO-I trials (1,16). In TIMI-14, the combination of
increasing doses of streptokinase and abciximab produced
only modest improvement in early TIMI flow grade 3 (34%
to 46%). The 1.5 MU streptokinase regimen plus abciximab
was discontinued after four of six patients developed a major
hemorrhage, one of whom developed an ICH.
The 50-mg dose of t-PA (15-mg bolus and 35-mg
infusion over 60 min) achieved substantial improvement in
TIMI grade 3 flow: 77% at 90 min as compared with 62%
for t-PA alone (p 5 0.01) (Fig. 5) (57). Overall patency at
90 min was achieved in 94% of patients with the combina-
tion of abciximab plus t-PA as compared with 78% for t-PA
alone. An even greater difference was observed at 60 min
when adding GPIIb/IIIa inhibition: the standard t-PA dose
achieved only 43% TIMI flow grade 3 at 60 min as
compared with 72% for 50 mg of t-PA plus abciximab (p 5
0.0009). Overall patency at just 60 min was achieved in 91%
of patients with the combination of abciximab and t-PA as
compared with 70% for t-PA. Myocardial perfusion as
assessed by ST segment resolution was also significantly
improved by the combination (45). Major hemorrhage was
similar among the t-PA plus abciximab and control groups,
;6% in each. In-hospital mortality was similar in all groups,
ranging from 3% to 5%. It appears from TIMI-14 that the
combination of GPIIb/IIIa inhibition with reduced-dose
thrombolytic therapy is a promising new regimen for en-
hancing both the speed and extent of reperfusion in acute
ST segment elevation in MI.
Preliminary results from the r-PA phase of TIMI-14 and
from the Strategies for Patency Enhancement in the Emer-
gency Department, a pilot study for GUSTO-IV–AMI,
have shown similar promising results using abciximab plus a
double bolus of reduced-dose r-PA (5 1 5 U). Preliminary
results from the latter trial show that TIMI flow grade 3 at
60 to 90 min was achieved in 63% of patients (58).
Additional angiographic trials with other GPIIb/IIIa inhib-
itors and large phase III trials are underway or being
planned. It is hoped these trials will help define a new era of
myocardial reperfusion therapy of “true thrombolysis”—that
is, lysis and inhibition of the fibrin, thrombin and platelet
components of occlusive thrombi.
SAFETY ISSUES
One of the main concerns in considering combination
therapy of a potent fibrinolytic agent and a potent antiplate-
let agent is bleeding, in particular, ICH (59). The review of
three randomized trials shows that GPIIb/IIIa inhibitors
produce no increase in ICH (60). Accumulated experience
with GPIIb/IIIa receptor inhibitors has shown a very low
associated incidence of ICH, from ;0.09% to 0.2%
(34,35,41,42,44,60–2). Therefore, one potential advantage
of combining reduced-dose fibrinolytic therapy plus a
GPIIb/IIIa receptor inhibitor and low-dose heparin is a
lower risk of ICH than found with current regimens.
Conclusions. There is a strong rationale, both clinical and
physiologic, for combining the potent GPIIb/IIIa receptor
inhibitors with fibrinolytic agents in acute ST segment
elevation MI: 1) current therapies need enhancement to
achieve early reperfusion and decreased risk of reocclusion;
Figure 5. Results from the Thrombolysis in Myocardial Infarction
(TIMI) 14 trial. Comparison of 90-min accelerated tissue-type
plasminogen activator (t-PA) with combination therapy using
abciximab (abcix) and reduced-dose t-PA (15-mg bolus and
35-mg infusion over 60 min) (t-PA 5 tissue-type plasminogen
activator). (Data from Antman et al. [57].)
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2) fibrinolytic and anticoagulant agents affect only fibrin and
thrombin; and 3) GPIIb/IIIa receptor inhibitors have been
shown to improve outcomes with a very low rate of ICH in
acute coronary syndromes and PCI.
Results observed in dose-ranging trials suggest that com-
bination therapy with reduced-dose fibrinolytic therapy,
GPIIb/IIIa inhibitors, aspirin and low-dose heparin appears
to be a promising and, in general, safe new strategy to
improve true “thrombolysis.” Whether the combination also
improves clinical outcomes as compared with current stan-
dard regimens must be addressed further in large-scale
randomized trials. Other issues that await exploration in-
clude the relative contributions of other antithrombins with
GPIIb/IIIa inhibitors, the cost-effectiveness of adding
GPIIb/IIIa inhibitors to thrombolytic therapy and the
potential role of GPIIb/IIIa inhibition in facilitating early
PCI post-thrombolysis in this era of “super-aggressive”
management of acute MI.
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